1. BONE MARROW INVOLVEMENT, BUT NO BLOOD INVOLVEMENT, IMPAIRS SURVIVAL IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: AN ANCILLARY STUDY OF THE REVAIL TRIAL. (12th June 2019) Authors: Lemonnier, F.; Safar, V.; Ferchiou, A.; Cottereau, A.; Bachy, E.; Cartron, G.; Moles‐Moreau, M.; Delmer, A.; Bouabdallah, R.; Voillat, L.; Parrens, M.; Casasnovas, O.; Cacheux, V.; Réguy, C.; Tilly, H.; Meignan, M.; Gaulard, P.; de Leval, L.; Delfau‐Larrue, M.; Haioun, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 278 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. INTEGRATIVE ANALYSIS OF FEATURES ASSOCIATED WITH TET2, IDH2, DNMT3A, AND RHOA MUTATIONS IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: A LYSA STUDY. (June 2017) Authors: Lemonnier, F.; Safar, V.; Cottereau, A.; Fataccioli, V.; Chaillol, I.; Pelletier, R.; Letourneau, A.; Dupuy, A.; Bossard, C.; Martin, A.; Robe, C.; Pelletier, L.; Pujals, A.; Bachy, E.; Delmer, A.; Moles Moreau, M.; Tilly, H.; Parrens, M.; Delfau‐Larue, M.; Missiaglia, E. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SERUM 2‐HYDROXYGLUTARATE, A PREDICTIVE BIOMARKER OF THE PRESENCE OF IDH2 MUTATIONS IN AITL PATIENTS. (June 2017) Authors: Broutin, S.; Dupuy, A.; Koscielny, S.; Fataccioli, V.; Lemonnier, F.; de Leval, L.; Robe, C.; Pujals, A.; Safar, V.; Delarue, R.; Delfau‐Larue, M.H.; Ribrag, V.; Haioun, C.; Gaulard, P.; Paci, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗